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(F= 3.16 and F= 3.15). The results from the regression model showed that as age 
increases, the expenditure rises especially at old ages. Patients from lower income 
groups spent more on ambulatory services than those in higher income groups, as 
well as individuals living in regions with very high level of social exclusion. Among 
other main determinants, individuals that looked for private health care attention 
along with those that perceived their health problems as severe increased their 
health expenditure. ConClusions: Out of pocket expenditure has been regres-
sive among health care users at IMSS. Therefore especial attention to lower income 
patients should be paid.
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objeCtives: Advanced Therapy Medicinal Products (ATMPs) include innovative 
and regenerative therapies such as gene therapy, somatic cell therapy medicinal 
product, and tissue engineered product. They represent major opportunity for curing 
many chronic disabling diseases. About 300 clinical trials for ATMPs are ongoing. 
Should some of these therapies reach their goal, which is considered to be likely, 
the impact on already constraint public payer budget would be dramatic. The objec-
tive of this project was to assess yearly cost of ATMPs for payers assuming a pay 
for performance split over years as long as disease do not re-emerge. Methods: 
We reviewed the economic impact of curing a range of chronic disabling conditions 
with ATMPs. We assumed that some ATMPs might cure a disease through one treat-
ment cycle. We computed cost per QALY by considering the avoided cost as well 
as disability associated to the diseases. We assumed a cost per QALY of £30,000/
QALY. We considered the payment will be based on yearly basis for each patient 
and not at the time of drug administration. This payment scheme was chosen as 
drug cost might not be affordable through a single payment. Results: Results 
showed that payment for ATMPs would range from about £10,000 to £480,000 per 
year and per cured patient depending on conditions. Avoided costs represented the 
main driver of the yearly ATMPs price, while generated QALY was comparatively 
smaller. These yearly payments are among the highest for rare disease driven by 
orphan drug prices avoided, while they are the lowest for chronic conditions with 
episodic clinical manifestation such as depression (assuming a recurrence every 5 
years). ConClusions: ATMPs cost might represent a source of important financial 
liability for public payers in a short future. This study raised awareness about need 
for new payment schemes for ATMPs and new sources of funding.
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objeCtives: To provide cost estimates and implications of irrational prescrib-
ing habits under the national health insurance scheme in the Kintampo North 
Municipality of rural Ghana. Methods: A retrospective cross sectional study car-
ried out for the whole of 2012. Vetted outpatient department claim forms submitted 
by all facilities to the Kintampo Municipal Mutual Health Insurance Scheme were 
used. Cost of all drugs and antibiotics per claim form were computed for four ran-
domly selected months of March, May, September and December to represent the 
first, second, third and fourth quarters of the year respectively. Results: A total of 
4238 claim forms were reviewed with a total of 12415 drugs prescribed within the 
period. The average costs of all drugs and antibiotics per prescription was GH¢ 4.50 
($ 2.25) and GH¢ 1.08 ($ 0.54) respectively. The average cost of antibiotics constituted 
24% of the average total cost of drugs per prescription. The average cost of all drugs 
and antibiotics was higher in private facilities (GH¢6.05 and GH¢1.34 respectively) 
than public facilities (GH¢ 3.65 and GH¢0.93 respectively). The difference in average 
cost of all drugs and antibiotics between private and public facilities was significant 
(p< 0.001each). The expected percentage average cost savings of all drugs and anti-
biotics assuming rational prescribing would have been more than 31.1% and 17.6% 
respectively. ConClusions: Average cost of drugs and antibiotics were high in this 
setting. Significant level of cost savings can be achieved if prescribing is optimal as 
recommended by the WHO.
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objeCtives: In Egypt, the Ministry of Health and Population (MOHP) sets phar-
maceutical prices from ex-factory to retail. In July 2012, the pricing policy changed 
from a cost plus to an external reference pricing method which was effective in 
October 2012. Our goal was to quantify the policy change impact on retail prices in 
pharmacies. Methods: We used MOHP lists and IMS data to pre-identify products 
with price changes. Purchase and sales data were obtained from a chain phar-
macy in Alexandria for all transactions pre- and post- the policy change (April-
Jun 2012 and 2013) to identify additional products and to validate the MOHP and 
IMS data. Changes in price per unit and per daily defined dose (DDD) were calcu-
lated. Results: A total of 205 products were subject to price changes, 70% were 
generics and 36% were essential drugs. The main therapeutic classes represented 
by the products were anti-infectives 15%, cardiovascular 14%, hair products 12%, 
vaginal-antiseptic 10%, psychotropics 8%, blood products 7% and analgesics 6%. 
Half of the products were produced by domestic private companies, 27% by mul-
tinational firms, 21% by state-owned companies and 2% were imported. Overall, 
the average price per physical unit increased by 53% (54% per DDD) for the affected 
n= 19). ConClusions: Manufacturer listed prices for oral formulations of NMEs 
at market entry are increasing over time. Orphan and priority review drugs have 
significant higher prices at market entry than other drugs.
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objeCtives: Pharmacoeconomic studies often require estimating the cost of drugs 
using manufacturer listed prices. There is a lack of studies assessing the relation-
ship between actual prices and manufacturer listed prices. This study compared 
the average sales price (ASP) and the average wholesale price (AWP) of single source 
brand drugs reimbursed by Medicare Part B for drugs used in physician offices 
in 2012. Methods: ASP data for the four quarters of 2012 were extracted from 
the Centers of Medicare and Medicaid Services (CMS) webpage, AWP data from 
the RedBook (Truven Health Analytics, Inc.) and drug information from the FDA 
website. Descriptive statistics and 95% confidence intervals were used in the analy-
sis. Results: CMS listed 571 products reimbursed by Medicare Part B in 2012. There 
were 243 (42.6% ) products with complete ASP and AWP information and without 
generic competition, of those 60.5% were new drugs applications (NDA), 22.2% thera-
peutic biologics (BLA), 12.8% other biologics, and 4.5% vaccines. The average ASP 
was 73.9%±34.5% the AWP in the first quarter of 2012, 72.4%±22.9% in the second 
quarter, 72.0%±24.5% in the third quarter, and 72.3%±26.5% in the fourth quarter. The 
relationship ASP/AWP in the fourth quarter was: 76.3%±89.0% (95%CI: 71.3%-81.3%, 
n= 147) for NDAs, 82.5%±9.6% (95%CI: 80.0%-85.1%, n= 54) for BLAs, 75.4%±38.9% 
(95%CI: 68.2%-82.7%, n= 31) for other biologics, 64.6%±18.6% (95%CI: 53.6%-75.6%, 
n= 11 )for vaccines, and 77.0%±70.7% (95%CI: 73.7%-80.4%, n= 243) for all products 
combined. ConClusions: The use of AWP overestimates the actual manufacturer 
average sales prices. ASP represented approximately 72% of the AWP across all 
products. This relationship was larger could explain the differences between actual 
and manufacturer listed prices.
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objeCtives: Elevated body temperature in critical care patients can increase 
complications and resource use. Automated targeted temperature management 
devices can be effective treatments for controlling patient temperature. This study 
estimated the cost impact of an innovative surface cooling system, the Arctic Sun® 
Temperature Management System, vs. alternative cooling methods (e.g., blankets 
and wraps), in critical care. Methods: A decision analytic model quantified the 
cost impact of Arctic Sun® vs. alternative cooling methods from a U.S. hospital 
perspective. An indirect comparison was conducted to inform the proportion of 
patients achieving target temperature. Based on a review of observational and ran-
domized studies, length of stay in the intensive care unit (ICU) and hospital ward 
stay were calculated for patients with and without elevated body temperature. 
Utilizing data from several critical care subgroups, it was estimated that 43% of 
patients are targeted for cooling. Medicare costs were assigned to hospital days, 
with average diagnosis-related group reimbursement integrated within the model. 
Acquisition costs included annual capital equipment assuming 5 year deprecia-
tion and disposables. One-year budget impact was estimated for 1,000 annual ICU 
patients. Results: Length of stay for ICU and ward days per patient was calculated 
for each comparator as follows: Arctic Sun® [2.07, 4.61] and alternative [2.54, 4.92]. 
Results predicted that use of Arctic Sun® vs. alternative cooling methods could save 
approximately $482,760 USD annually. Considering average reimbursement, these 
cost savings translate into a hospital margin per patient of $1,110. Sensitivity analy-
ses including nursing time predicted further cost savings (i.e., an additional $268,070 
per year). Results were robust to several alternative assumptions. ConClusions: 
This analysis suggests that use of Arctic Sun® in critical care patients may result 
in improved patient care and important cost-savings for U.S. hospitals. Additional 
data is required to further substantiate the relationship between resource utiliza-
tion and temperature cooling.
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objeCtives: The aim of this study is to identify the determinants of out of pocket 
expenditure, defined as the spending on physician visits, drugs and laboratory and 
ancillary tests, among users of the ambulatory health services at IMSS. Methods: 
Data from the National Health Survey 2012 was used to estimate the total and 
mean out of pocket expenditure among ambulatory health care users. A statisti-
cal analysis to test for differences in the mean expenditure with gender, age and 
income was performed. A multiple regression model was carried out to identify 
the impact of factors associated with out of pocket payments made by the users 
of these services. Results: 29% of health care users that reported any type of out 
of pocket spending were affiliated at IMSS. Among them, the total and mean out 
of pocket expenditure was of USD$ 29,259 and USD$15 respectively. The highest 
expenditure was associated with the physician visits (61%), followed by the spending 
on laboratory and ancillary services (30%) and drugs (9%). There was not a statisti-
cally significant difference between gender and total expenditure (t= 0.24). On the 
contrary a significant statistical difference was found with groups of age and income 
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that has been implemented in Turkey since December 2012. Total volume of PHI in 
Turkey is expected to expand more as the scope of the supplementary health insur-
ance implementation increases. There exists a diminishing trend of OOP expenses 
across all three countries however this is again relatively much lower for Turkey. 
Since 2003, Turkey has been implementing a Health Transformation Program where 
PHI is expected to play a crucial role to reduce OOP health expenditure. Despite this 
ten-year program, OOP spending has decreased slightly (11%) when compared to 
South Africa where there is a threefold decrease. ConClusions: Turkey has still 
room to improve its private insurance system along with its public system to reduce 
OOP payments. South Africa with private dominant health insurance system and 
lower OOP spending is trying to transfer its resources towards a national health 
insurance system. United States stands as a stabilized private dominant health 
insurance model which significantly differs from Turkey and South Africa.
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objeCtives: The need to use real-world data to support Health Care decision was 
the main driver for the Italian Inter-University Consortium (CINECA) to set-up a 
population-based patient centric database (ARNO Observatory) which integrates 
big administrative data from National/ Regional Information Systems to monitor 
health economics, patient’s outcomes and measure health performance in the 
real world. Methods: On a population of almost 12 million, since 1987, ARNO 
Observatory routinely collects and integrates NHS administrative data for each 
single patient with high quality and complete information. ARNO provides com-
prehensive data referred to patient as: demographics, outpatient drug prescrip-
tions, inpatient hospital discharges, imaging and lab tests prescriptions. From 
ARNO Observatory we carried out analyses of population or on specific cohorts 
to evaluate prevalence of chronic disease, co-morbidities and cost of total burden 
of illness. Results: From a cohort of 2,5 million of ARNO population, one third 
subjects has at least one chronic disease during 2012 and this proportion rises with 
ages (84% in elderly over 80 years). The most common chronic disease is hyper-
tension (23%), followed by COPD/asthma (13%), dyslipidemia (10%) and diabetes 
(6,3%). Integration of different data flows led to the evaluation of cost of illness 
which varies from 2.000€ for hypertension or 2.800€ for diabetes to 12.000€ for Acute 
Coronary Syndrome. Most part of this cost is due to hospitalization (49% vs 40% for 
drugs and 12% for diagnostic examination and lab tests). Cost of illness is strictly 
correlated to age and presence of co-morbidities, actually a considerable number 
of patients has more than one disease (17%), in elderly this percentage rises up 
to 50%. ConClusions: A big data infrastructure is very important to integrate 
administrative and clinical data for real world analyses and it is a valid instrument 
to support clinical governance and clinical research decision making.
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objeCtives: Estimate the financial savings associated with participation in a 
transitional case management (TCM) program offered by Optum. Nurses managed 
cases via telephone and face-to-face interventions following member’s inpatient 
admission. The program was designed to improve care and help save money by 
better managing post-discharge care of the participants. Methods: Propensity-
score-weighted difference-in-difference multiple regression analyses were used to 
estimate savings in total health care expenditures associated with active engage-
ment in the CAD program. Factors associated with the program participation and 
savings were also found via logistic regression. The study included cohorts of 80,032 
participants and 29,054 non-participants who qualified for the program between 
July 2011 and December 2012. Pre- and post-program engagement periods extended 
for up to 12 months before and after the dates members qualified for the program. 
Regression models controlled for age, gender, and health conditions along with 
inferred demographic characteristics such as minority status, education, income, 
and the supply of health care services in members’ zip code of residence. Results: 
The regression-adjusted average cost trend was $231 lower per member per month 
for program participants. About 42.4% of the participants were managed in a way 
that their cost savings exceeded the costs of providing the program. Factors asso-
ciated with engagement were not always associated with program savings. For 
example, lower income and lower supply of health care service areas were associ-
ated with lower participation rates but higher saving. On the other hand, those with 
higher risk scores and in higher age group were more likely to engage and also more 
likely to be managed in a way that lead to savings as well. ConClusions: The TCM 
program helped to generate savings. Analyses of participation and savings allowed 
program providers to understand the pockets of program success and streamline 
future efforts to improve the program.
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objeCtives: Taiwan’s National Health Insurance, established in 1995, has offered 
every citizen nearly equal financial access to comprehensive health services and 
provides all citizens with financial risk protection from large medical expenses. 
Existing data reported that purchasing private life and annuity insurances is popular 
in Taiwan, with an average of 2.3 contracts per person and 18% of GDP invested in 
products. The average prices per physical unit and price changes after the policy 
varied significantly by manufacturer type: 1.8 EGP (0.26 $USD) for drugs produced by 
state-owned companies increased by 238%, 2.3 EGP for domestic-private company 
products increased by 10%, 13 EGP for multinationals products decreased by 6%, 
and 41 EGP for imported products increased by 13%. ConClusions: Switching 
to a referent price policy for pharmaceuticals resulted in considerable percentage 
increase, on average, for products where a price change occurred. However, the 
nominal effect was attenuated because the biggest proportional changes occurred 
on the lowest cost drugs.
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objeCtives: To understand hospitalization costs, costs covered by insurance and 
disease distribution among urban inpatients with basic health insurance (BHI) 
in China between 2010 and 2011, providing data evidence for the government 
to improve BHI policies and drug regulation system in the further. Methods: A 
nationwide, cross-sectional sampling of urban inpatients with BHI was conducted 
in mainland China. A retrospective analysis was adopted and all results were 
extrapolated to the whole country according to the population, economics and 
other factors in the inpatients’ cities. The statistics analysis software was SQL Server 
2003. Results: There were 38.2 million hospitalization cases after extrapolating 
(sample= 375822) in 2011, with an increase of 21.42% than that of the previous year. 
Three-class hospitals received more hospitalization cases (43.56% of the total) in 
2011 than the previous year (40.10% of the total). Average hospitalization cost per 
visit in 2011 was 8210 RMB, an increase of 1.90% from the previous year. Remarkably, 
medication expenses accounted for about 49%, which was approximately equal to 
the previous year. The expenses covered by BHI accounted for 68.39% for each visit, 
which was higher than that of the previous year. Cerebrovascular disease had the 
most hospitalization cases (9.11% of the total), followed by cancer, ischemic heart 
disease, Hypertension and diabetes. The total hospitalization cost of cancer (37.8 bil-
lion RMB) was the highest, followed by cerebrovascular disease (32.8 billion RMB) and 
ischemic heart disease (25.7 billion RMB). ConClusions: The average hospitaliza-
tion costs per visit and total hospitalization costs all increased. And rational drug 
use should be still paid more attention since the drug costs percentage was steadily 
high. Helping inpatients select proper hospitals to see doctors and strengthening the 
administration of diseases cost highly will be helpful for reducing the medical costs.
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objeCtives: Analysis of large datasets such as claims and health care utilization 
databases has become a routine way that drug, device and diagnostic manufacturers 
understand current treatment pathways and project market potential for develop-
ment products. The time, resources, and costs associated with these data analyses 
can be a barrier for small- to mid-size companies operating under the pressure of 
lean development processes. We sought to analyze the current published litera-
ture on claims analyses in four therapeutic areas (cardiovascular, ophthalmology, 
oncology, and women’s health) to better understand the size of companies engag-
ing in this type of research. Methods: A literature review of published articles 
from January 1, 2000 – December 31, 2013 was conducted to better understand the 
analyses of large datasets being conducted by company size. The data were then 
abstracted to obtain the following data: therapeutic area, funding support for data 
analysis, company size, large dataset utilized, approximate cost of obtaining data, 
approximate cost of analyzing data, approximate US patient population for drug/
device/diagnostic under development. Results: Analyses of large datasets were 
just as likely to be conducted by government and academic institutions as private 
sector organizations (research firms and manufacturers). Of the 35 articles that 
met inclusion criteria in cardiovascular disease, 19 conducted by private sector 
organizations. For the 19 analyses conducted by private sector organizations, 3 
were conducted by manufacturers, of which two were large pharmaceutical compa-
nies and 1 was a nationwide pharmacy chain. ConClusions: None of the claims 
data conducted by manufacturers were small- to mid-size companies. It is unclear 
whether this is due to the cost of data and analysis or the desire to have a seem-
ingly unbiased third-party author. Further research is needed to determine why 
small- to mid-size drug, device or diagnostic manufacturers are not engaging in 
this type of research.
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objeCtives: This poster presents a comparative analysis of the private health care 
insurance systems (PHI) in Turkey, United States and South Africa. Methods: OECD 
publications, Turkish Private Health Insurance Association, World Bank Reports, 
Publications of Turkish Social Security Institution (SSI) and official web pages of US 
and South Africa Departments of Health are examined for 2001-2011. Results: In 
comparison to Turkey; United States and South Africa have similar characteristics 
in terms of PHI dependence prevailing with a higher coverage. Due to lower PHI level 
in Turkey, Out of Pocket (OOP) payments constitute a significantly higher amount. 
In Turkey, PHI coverage has almost tripled over the last 10 years, but still accounts 
only for 3.40 % of the total population. The trend towards strengthening the PHI is 
basically due to the promotion of PHI solutions such as supplementary coverage 
